Toboroz
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· 2. fázis· Genmab· Forrás
Toboroz
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· 3. fázis· Takeda· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235· 3. fázis· Takeda· Forrás
Toboroz
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048· 3. fázis· Corvus Pharmaceuticals, Inc.· Forrás
Toboroz
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
NCT06058585· 3. fázis· The George Institute· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· 3. fázis· Kartos Therapeutics, Inc.· Forrás
Toboroz
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás
Toboroz
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· 3. fázis· United Therapeutics· Forrás
Fut, nem toboroz
Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)
NCT07579390· Helsinki University Central Hospital· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
NCT05393791· 2. fázis· Leiden University Medical Center· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Meghívásos bevonás
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· 3. fázis· United Therapeutics· Forrás
Toboroz
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616· 3. fázis· University College, London· Forrás
Fut, nem toboroz
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· 3. fázis· BeOne Medicines· Forrás
Toboroz
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130· 1/2. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541· 1/2. fázis· Genmab· Forrás
Fut, nem toboroz
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
NCT04419402· 2. fázis· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Forrás
Fut, nem toboroz
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· 3. fázis· University of Sydney· Forrás
Fut, nem toboroz
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· 1/2. fázis· Dizal Pharmaceuticals· Forrás
Toboroz
The EXCEL Registry of Patients Requiring ECMO
NCT03793257· Australian and New Zealand Intensive Care Research Centre· Forrás
Fut, nem toboroz
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037· 1/2. fázis· Genmab· Forrás
Fut, nem toboroz
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200· 4. fázis· Pharmacyclics Switzerland GmbH· Forrás
Fut, nem toboroz
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02170090· 3. fázis· Universitätsklinikum Hamburg-Eppendorf· Forrás
Fut, nem toboroz
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· 3. fázis· University of Sydney· Forrás
Fut, nem toboroz
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
NCT02446444· 3. fázis· University of Sydney· Forrás
Fut, nem toboroz
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01924819· 2/3. fázis· Australasian Gastro-Intestinal Trials Group· Forrás
Fut, nem toboroz
Radiotherapy - Adjuvant Versus Early Salvage
NCT00860652· Trans Tasman Radiation Oncology Group· Forrás